This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Dashboard: Filter Bricks
Main page content
This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).
This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.
This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.
This guide highlights the use of medication-assisted treatment (MAT) for opioid use disorder in drug courts. It reviews effective medications, including methadone, buprenorphine, and naltrexone. The guide also provides strategies to increase the use of MAT in drug court programs.